The Representative Research and Production Base for Series of Hepatitis A Vaccines in China

As early as in 1974, IMBCAMS independently established a human diploid cell line, KMB17. Its establishment provides a base for the subsequent development of new vaccines from human diploid cells.

In 1992, the live-attenuated HAV (liquid) from IMBCAMS was firstly permitted to market.

The inactivated HAV, WEISAIRUIAN®，and the freeze-dried live-attenuated HAV, WEISAIRUIJI®，were put into Chinese market in 2003 and 2006, respectively.